Achiron, Anat

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet

Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling

Cited by 942

Reduced cancer incidence among patients with schizophrenia

Barak, Y., Achiron, A., Mandel, M., Mirecki, I., & Aizenberg, D. (2005) · Cancer

Schizophrenia research and treatmentGlobal Cancer Incidence and Screening

Cited by 159

Aquaporin 4 molecular mimicry and implications for neuromyelitis optica

Vaishnav, R. A., Liu, R., Chapman, J., Roberts, A. M., Ye, H., Rebolledo-Mendez, J. D., Tabira, T., Fitzpatrick, A. H., Achiron, A., Running, M. P., et al. (2013) · Journal of Neuroimmunology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 36

Dysregulation of affect in multiple sclerosis: New phenomenological approach

HAREL, Y., BARAK, Y., & ACHIRON, A. (2007) · Psychiatry and Clinical Neurosciences

Multiple Sclerosis Research StudiesMental Health and Psychiatry

Cited by 27